VIRADIA: a virtual reality app for neurological and cognitive testing
Validation Study of VIRADIA: A Virtual Reality Diagnostic Platform for the Assessment of Neurological and Cognitive Functions
This project tests whether the VIRADIA virtual reality app gives comparable results to standard paper or in-person neurological and cognitive tests for adults with and without neurological conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Gametherapy Academic / other |
| Locations | 1 site (Nitra, Nitra Region) |
| Trial ID | NCT07268079 on ClinicalTrials.gov |
What this trial studies
The VIRADIA validation uses a within-subjects, paired design in which healthy volunteers and people with neurological diagnoses complete both standard (paper or face-to-face) and VR versions of nine common clinical tests. Test order is randomly assigned to control for order effects, and measures cover fine motor coordination (9-Hole Peg Test), gait and balance (6‑Meter Walk, TUG‑M, Functional Reach), processing speed and attention (SDMT), and visuospatial/executive function (Clock Drawing, Trail Making). Demographic and clinical data are recorded and participants complete a brief questionnaire on VR tolerability and subjective experience. Analyses focus on convergent validity (agreement between VR and standard scores) and discriminative validity (ability of VR measures to distinguish healthy controls from neurological patients).
Who should consider this trial
Good fit: Ideal candidates are adults aged 18–80 who can give informed consent, have adequate vision and hearing, and are either healthy volunteers or have a confirmed neurological diagnosis (for example Parkinson's disease or multiple sclerosis).
Not a fit: Patients with severe cognitive impairment (e.g., MMSE <24), major motor disabilities that prevent using a VR controller, uncorrected visual or vestibular conditions causing VR intolerance, acute psychiatric conditions, or current substance abuse are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, VIRADIA could provide a standardized, more accessible way to perform neurological and cognitive tests that supports clinic-based or remote monitoring and earlier detection of change.
How similar studies have performed: Previous VR adaptations of cognitive and motor assessments have shown promising correlations with traditional measures, but large-scale, cross-condition validation data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-80 years. * Ability to provide informed consent. * Adequate vision and hearing to complete testing. * For the neurological group: confirmed diagnosis of a neurological disorder (e.g., Parkinson's disease, multiple sclerosis, or similar). * For the control group: no history of neurological or psychiatric disease. Exclusion Criteria: * Severe cognitive impairment (MMSE \< 24 or equivalent clinical judgment). * Acute neurological or psychiatric condition interfering with testing. * Severe motor disability preventing task performance (e.g., inability to use VR controller). * Current substance abuse. * Uncorrected visual impairment or vestibular disorder leading to intolerance of VR.
Where this trial is running
Nitra, Nitra Region
- INNER s.r.o., Fatranská 873/12, 94901 Nitra — Nitra, Nitra Region, Slovakia (Recruiting)
Study contacts
- Principal investigator: Ingrid Menkyova, MD, PhD.
- Study coordinator: Martin Polak, Dr.
- Email: martin@gametherapy.eu
- Phone: +421915546098
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.